DE69617211D1 - Hepatitis b impfstoff - Google Patents

Hepatitis b impfstoff

Info

Publication number
DE69617211D1
DE69617211D1 DE69617211T DE69617211T DE69617211D1 DE 69617211 D1 DE69617211 D1 DE 69617211D1 DE 69617211 T DE69617211 T DE 69617211T DE 69617211 T DE69617211 T DE 69617211T DE 69617211 D1 DE69617211 D1 DE 69617211D1
Authority
DE
Germany
Prior art keywords
impfstoff
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69617211T
Other languages
German (de)
Other versions
DE69617211T2 (en
Inventor
Pierre Hauser
Marie-Josephe Garcon
Pierre Desmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69617211(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Beecham Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE69617211D1 publication Critical patent/DE69617211D1/en
Publication of DE69617211T2 publication Critical patent/DE69617211T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69617211T 1995-02-25 1996-02-15 HEPATITIS B VACCINE Expired - Lifetime DE69617211T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions
PCT/EP1996/000681 WO1996026741A1 (en) 1995-02-25 1996-02-15 Hepatitis b vaccine

Publications (2)

Publication Number Publication Date
DE69617211D1 true DE69617211D1 (en) 2002-01-03
DE69617211T2 DE69617211T2 (en) 2002-07-25

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617211T Expired - Lifetime DE69617211T2 (en) 1995-02-25 1996-02-15 HEPATITIS B VACCINE

Country Status (36)

Country Link
US (1) US5972346A (en)
EP (1) EP0810877B1 (en)
JP (1) JP3881015B2 (en)
KR (1) KR100365373B1 (en)
CN (1) CN1101225C (en)
AP (1) AP766A (en)
AR (1) AR002279A1 (en)
AT (1) ATE209045T1 (en)
AU (1) AU695921B2 (en)
BG (1) BG101851A (en)
BR (1) BR9607458A (en)
CA (1) CA2212552C (en)
CZ (1) CZ288417B6 (en)
DE (1) DE69617211T2 (en)
DK (1) DK0810877T3 (en)
EA (1) EA199700126A1 (en)
ES (1) ES2166879T3 (en)
FI (1) FI118118B (en)
GB (1) GB9503863D0 (en)
HK (1) HK1004117A1 (en)
HU (1) HU224832B1 (en)
IL (1) IL117249A (en)
MA (1) MA23814A1 (en)
MX (1) MX9706450A (en)
MY (1) MY113428A (en)
NO (1) NO319394B1 (en)
NZ (1) NZ302674A (en)
OA (1) OA10612A (en)
PL (1) PL182679B1 (en)
PT (1) PT810877E (en)
SA (1) SA96160633B1 (en)
SK (1) SK115097A3 (en)
TR (1) TR199700849T1 (en)
TW (1) TW467745B (en)
WO (1) WO1996026741A1 (en)
ZA (1) ZA961460B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
IL142395A0 (en) * 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
CU22871A1 (en) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech FORMULATIONS CONTAINING PARTICULARS SIMILAR TO VIRUS AS IMMUNOPOTENCERS BY MUCOSAL ROUTE
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (en) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech SURFACE ANTIGEN OF THE HEPATITIS B VIRUS AS A MUCOSOPT IMMUNOPOTENTIATOR, RESULTS FORMULATIONS
CA2598079A1 (en) * 2005-02-16 2006-08-24 Novartis Vaccines And Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3d-mpl
EA014314B1 (en) * 2005-08-02 2010-10-29 Новартис Вэксинес Энд Дайэгностикс Срл Reducing interference between oil-containing adjuvants and surfactant-containing antigens
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
DK1951299T3 (en) 2005-11-04 2012-04-02 Novartis Vaccines & Diagnostic Influenza vaccines containing combinations of particulate adjuvants and immune enhancers
EP1951298A1 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
CN100415294C (en) * 2005-12-23 2008-09-03 中国农业大学 Medicine for treating and/or preventing hepatitis B
HUE049580T2 (en) 2006-01-27 2020-09-28 Seqirus Uk Ltd Influenza vaccines containing hemagglutinin and matrix proteins
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
EP1862176A1 (en) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
EP1862177A1 (en) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (en) 2006-12-06 2011-03-03 ノバルティス アーゲー Vaccines containing antigens from four strains of influenza virus
PL2185191T3 (en) 2007-06-27 2013-02-28 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
LT3178490T (en) 2009-07-15 2022-07-25 Glaxosmithkline Biologicals S.A. Rsv f protein compositions and methods for making same
EP4144368A1 (en) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
HUE048777T2 (en) 2011-05-13 2020-08-28 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (en) * 1989-07-25 1997-10-15 Smithkline Biolog ANTIGENS AND METHODS FOR THE PRODUCTION THEREOF
CA2109714A1 (en) * 1991-05-29 1992-12-10 Frederic H. Moll Retraction apparatus and methods for endoscopic surgery
MA22842A1 (en) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog PROCESS FOR THE PREPARATION OF VACCINE COMPOSITIONS.
ES2334181T3 (en) * 1992-05-23 2010-03-05 Glaxosmithkline Biologicals S.A. COMBINED VACCINES THAT INCLUDE HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS.
JP4028593B2 (en) * 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 3-O deacylated monophosphoryl lipid A-containing vaccine composition
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
KR19980702480A (en) 1998-07-15
ZA961460B (en) 1996-08-29
CA2212552A1 (en) 1996-09-06
BR9607458A (en) 1998-06-30
HUP9801242A3 (en) 2000-08-28
EP0810877A1 (en) 1997-12-10
PT810877E (en) 2002-04-29
KR100365373B1 (en) 2003-07-07
PL321966A1 (en) 1998-01-05
AP9701060A0 (en) 1997-10-31
SK115097A3 (en) 1998-02-04
JP3881015B2 (en) 2007-02-14
ATE209045T1 (en) 2001-12-15
AR002279A1 (en) 1998-03-11
EP0810877B1 (en) 2001-11-21
NO319394B1 (en) 2005-08-08
MY113428A (en) 2002-02-28
TW467745B (en) 2001-12-11
TR199700849T1 (en) 1998-01-21
AU4878096A (en) 1996-09-18
MA23814A1 (en) 1996-10-01
DE69617211T2 (en) 2002-07-25
CZ267497A3 (en) 1998-02-18
PL182679B1 (en) 2002-02-28
NO973873D0 (en) 1997-08-22
EA199700126A1 (en) 1998-02-26
US5972346A (en) 1999-10-26
FI973457A (en) 1997-08-22
DK0810877T3 (en) 2002-02-25
JPH11501018A (en) 1999-01-26
HU224832B1 (en) 2006-03-28
WO1996026741A1 (en) 1996-09-06
CN1101225C (en) 2003-02-12
SA96160633B1 (en) 2005-10-15
CN1176604A (en) 1998-03-18
OA10612A (en) 2002-08-29
FI118118B (en) 2007-07-13
CZ288417B6 (en) 2001-06-13
NO973873L (en) 1997-08-22
CA2212552C (en) 2006-07-11
BG101851A (en) 1998-04-30
HK1004117A1 (en) 1998-11-20
MX9706450A (en) 1998-07-31
FI973457A0 (en) 1997-08-22
IL117249A0 (en) 1996-06-18
GB9503863D0 (en) 1995-04-19
ES2166879T3 (en) 2002-05-01
HUP9801242A1 (en) 1998-08-28
IL117249A (en) 2000-11-21
AP766A (en) 1999-09-17
NZ302674A (en) 1999-01-28
AU695921B2 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
DE69617211D1 (en) Hepatitis b impfstoff
PL324453A1 (en) Sold greasea
DE59607964D1 (en) Oxymethoxy-3-aryl-pyron-derivate
DE59607241D1 (en) Endotracheal-tubus
HUP9801128A3 (en) Fucopeptides
DE59605001D1 (en) Luftreinigungsgerät
DE59602030D1 (en) Zellige polyurethan-elastomere
DE59602888D1 (en) Breitstreckaggregat
DE59602283D1 (en) Inchbremseinrichtung
ZA946158B (en) Methyl 3-methoxy-2-phenyl-acrylates
DE59505396D1 (en) Handhobelmaschine
AP9600802A0 (en) Libricant
DE59600830D1 (en) Breitstrahldüse
DE59604506D1 (en) Rückkühlsystem
DE59604913D1 (en) Carbonylverbindungen
AU1105P (en) DALESE Metrosideros excelsus
SI0810877T1 (en) Hepatitis b vaccine
GB9517905D0 (en) Improved can
MD868B1 (en) Apple-tree variety Sperantsa
MD881B1 (en) Apple-tree variety Focushor
GB9508704D0 (en) Virus
BG99666U (en) Sun-heater
AU131835S (en) Gamesboard
AU124982S (en) Snow - bike
AU124825S (en) Quiltcover

Legal Events

Date Code Title Description
8364 No opposition during term of opposition